insights_auto
Why is ARCT up 2.08%?
Dive Deeperchevron_right
ARCT:NASDAQ
Arcturus Therapeutics Holdings Inc
$10.56
arrow_upward
+2.08%(+0.22) 1D
Oct 19, 10:51:05 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARCT...
Open
$10.47
High
$10.79
Low
$10.37
Mkt. cap
300.01M
Avg. vol.
758.06K
Volume
67.22K
52-wk high
$24.17
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
Open
$10.47
High
$10.79
Low
$10.37
Mkt. cap
300.01M
Avg. vol.
758.06K
Volume
67.22K
52-wk high
$24.17
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
News stories
From web sources and news partners
finance.biggo.com
·
40 minutes ago
He makes 3 decisions a year (and beat the S&P 500 for 11 years)｜My First Million
Devdiscourse
·
29 minutes ago
US STOCKS-S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
RealMoney Pro
·
31 minutes ago
Charting the Markets: The S&P Is Still Bullish. But for How Long?
TradingView
·
1 hour ago
The Dow Jones Index Opens 0.08% Lower
Profile
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
About Arcturus Therapeutics Holdings Inc